Drug Profile
Levetiracetam - GlaxoSmithKline/Otsuka Pharmaceuticals/UCB
Alternative Names: E Keppra; E Keppra Dry syrup 50%; EKeppra; Keppra; Keppra XR; L-059; Levetiracetam IR; Levetiracetam XR; SIB-S1; UCB-059; UCB-22059; UCB-L059Latest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator UCB
- Developer Ache Laboratories; GSK; Otsuka Pharmaceutical; UCB
- Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
- Mechanism of Action SV2A protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Epilepsy; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
- Discontinued Anxiety disorders; Neuropathic pain; Parkinsonian disorders
Most Recent Events
- 01 Mar 2024 Launched for Partial epilepsies (Adjunctive treatment, In children, In infants, Monotherapy) in Japan (IV)
- 28 Jul 2023 UCB Pharma completes a phase III trial in Partial epilepsies (Adjunctive treatment, In children, In infants, Monotherapy) in Japan (IV) (PO) (NCT03340064)
- 30 Jun 2023 Launched for Partial epilepsies (Adjunctive treatment, In children, In infants, Monotherapy) in Japan (PO)